Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23422001 | 0.89 | SMN1; SMN2 (0.41) | SMN1; SMN2RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL23930834 | 0.87 | ALOX15 (0.47) | SMN1; SMN2RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL10288449 | 0.86 | ALDH1A1 (0.58) | SMN1; SMN2RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL2825471 | 0.85 | RAB9A (0.50) | SMN1; SMN2RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL2824661 | 0.85 | SMN1; SMN2 (0.48) | SMN1; SMN2RAB9AMEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL2825470 | 0.83 | RAB9A (0.49) | SMN1; SMN2RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL13141309 | 0.82 | SMN1; SMN2 (0.46) | SMN1; SMN2RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL23930934 | 0.82 | KMT2A (0.48) | SMN1; SMN2RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL2825380 | 0.82 | SMN1; SMN2 (0.46) | SMN1; SMN2RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL25269324 | 0.80 | ALDH1A1 (0.41) | RAB9AMEN1KMT2ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12479834-B2 | Phenol compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-11-25 | — | — | US | disclosed |
| EP-4192831-B1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20240376061-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2024-11-14 | — | — | US | disclosed |
| US-12065430-B2 | Indazole compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-08-20 | — | — | US | disclosed |
| US-11897851-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| EP-3871673-B1 | NOVEL INDAZOLE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2024-01-03 | — | — | EP | disclosed |
| CN-116323599-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20230192633-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192633-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| EP-2149561-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2010-02-03 | — | — | EP | disclosed |
| EP-2149561-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2010-02-03 | — | — | EP | disclosed |
| US-7371749-B2 | Benzothiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371749-B2 | Benzothiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371749-B2 | Benzothiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | disclosed |
| CN-1989139-A | Benzothiazole derivatives | HOFFMANN LA ROCHE (CH) | 2007-06-27 | — | — | CN | disclosed |
| EP-1773827-A1 | BENZOTHIAZOLE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-18 | — | — | EP | disclosed |
| US-20060019949-A1 | Benzothiazole derivatives | HOFFMANN-LA ROCHE INC. | 2006-01-26 | — | — | US | disclosed |
| WO-2006008041-A1 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-26 | — | — | WO | disclosed |
| WO-2006008041-A1 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192633-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | SMN1; SMN2 1134/4885RAB9A 806/4885MEN1 418/4885 |
| US-12065430-B2 | Indazole compound or salt thereof | RCOR3, H1-3, BICRA | SMN1; SMN2 3985/4885RAB9A 534/4885MEN1 905/4885 |
| US-20060019949-A1 | Benzothiazole derivatives | CNR2, CNR1, CHRNA2 | SMN1; SMN2 162/4885RAB9A 1898/4885MEN1 4714/4885 |
| US-11897851-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, GCGR | SMN1; SMN2 1134/4885RAB9A 806/4885MEN1 418/4885 |
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, VIP | SMN1; SMN2 2164/4885RAB9A 853/4885MEN1 1749/4885 |
| US-12479834-B2 | Phenol compound or salt thereof | REN, MLX, MYB | SMN1; SMN2 3261/4885RAB9A 876/4885MEN1 2667/4885 |
| US-20240376061-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | SMN1; SMN2 1134/4885RAB9A 806/4885MEN1 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.